Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online May 22, 2008
Stem Cells Vol. 26 No. 8 August 2008, pp. 2164 -2172
doi:10.1634/stemcells.2007-1049; www.StemCells.com
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
2007-1049v1
26/8/2164    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oostendorp, R. A.J.
Right arrow Articles by Götze, K. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oostendorp, R. A.J.
Right arrow Articles by Götze, K. S.

TRANSLATIONAL AND CLINICAL RESEARCH

Oncostatin M-Mediated Regulation of KIT-Ligand-Induced Extracellular Signal-Regulated Kinase Signaling Maintains Hematopoietic Repopulating Activity of LinCD34+CD133+ Cord Blood Cells

Robert A.J. Oostendorpa, Siv Gilfillana, Amanda Parmara, Matthias Schiemannb,f, Stefanie Marza, Markus Niemeyerc, Sabine Schilld, Edelburga Hammerschmide, Volker R. Jacobsc, Christian Peschela, Katharina S. Götzea

a3rd Department of Internal Medicine,
bDepartment of Microbiology and Immunology,
cDepartment of Obstetrics and Gynaecology,
dDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany;
eInstitute for Experimental Oncology and
fClinical Cooperation Group "Antigen-specific Immunotherapy," Helmholtz Zentrum München, Munich, Germany

Key Words. CD34 • Stem cell • NOD/SCID • KIT ligand • Oncostatin M • ERK

Correspondence: Correspondence: Robert A.J. Oostendorp, Ph.D., Laboratory of Stem Cell Physiology, III. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Ismaningerstrasse 22, 81675 Munchen, Germany. Telephone: +49 89 4140 6056; Fax: +49 89 4140 6057; e-mail: oostendorp{at}lrz.tum.de

Received on December 11, 2007; accepted for publication on May 14, 2008.

First published online in STEM CELLS EXPRESS  May 22, 2008.


We investigated whether KIT signaling was sufficient to maintain human hematopoietic stem cells in culture or whether, as with murine stem cells, signaling through glycoprotein 130 (gp130) is additionally required. Sorted CD34+CD133+(CD33/CD38/CD71) cells from human umbilical cord blood (UCB) were cultured in the presence of combinations of KIT-ligand (KL) and the gp130 stimulating molecule oncostatin M (OSM). We found that OSM increased KL-induced proliferation, which was accompanied by an expansion in numbers of mature progenitors colony-forming cells (CFC, CAFCw2). More primitive progenitors, CAFCw6 and long-term culture-CFC, were not maintained by KL as a single factor. Although addition of OSM did not improve survival, the KL/OSM combination showed improved maintenance of immature progenitors as well as higher CD34 expression. Similarly, both KL and OSM were required to maintain NOD/SCID-repopulating activity. In experiments to investigate the underlying mechanism, we found that extracellular signal-regulated kinase (ERK) and its downstream target p90 ribosomal S6 kinase were activated by KL and downregulated by the inclusion of OSM during stimulation. The p38 mitogen-activated protein kinase (p38 MAPK) was not modulated by either KL or OSM. Indeed, many of the effects of OSM (increased cell division, maintenance of CFC, and maintenance of high CD34 expression) could be mimicked by using the mitogen-activated protein kinase kinase inhibitor U0126. More importantly, NOD/SCID-repopulating activity was preserved in the KL/U0126-stimulated cells, but not in cells stimulated with a combination of KL and the p38 MAPK inhibitor SB203580. Our results show that the loss of repopulating activity during KL stimulation is counteracted by OSM through the downregulation of ERK pathway signaling.

Disclosure of potential conflicts of interest is found at the end of this article.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 2008 by AlphaMed Press.